Walker, J;
Hutchison, P;
Ge, J;
Zhao, D;
Wang, Y;
Rothwell, PM;
Gaziano, JM;
... Hawkey, C; + view all
(2018)
Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin.
Ecancermedicalscience
, 12
, Article 813. 10.3332/ecancer.2018.813.
Preview |
Text
can-12-813.pdf - Published Version Download (314kB) | Preview |
Abstract
Acetylsalicylic acid was first synthesised by Dr FeIix Hoffman on 10th August 1897 and Aspirin was born. It quickly became the best-known pain killer in the world and in the 120 years since this event, aspirin has continued to attract interest, innovation and excitement. Set within the walls of the preserved ruins of Rudolf Virchow's lecture hall at Charité, within Berlin's Museum of Medical History, the International Aspirin Foundation's 28th Scientific Conference served to facilitate international, multi-disease, multidisciplinary discussion about the current understanding of aspirin's mechanisms of action and its utility in modern medicine as well as ideas for future research into its multifaceted applications to enhance global health. In addition to the delegates in Berlin, 300 medical doctors at the 19th Annual Scientific Congress of the Chinese Society of Cardiology were able to join the cardiology sessions from Taiyuan, Shangxi province via a live streaming link to and from China. This led to useful discussion and allowed a truly international perspective to the meeting.
| Type: | Article |
|---|---|
| Title: | Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3332/ecancer.2018.813 |
| Publisher version: | http://dx.doi.org/10.3332/ecancer.2018.813 |
| Language: | English |
| Additional information: | © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | Lynch syndrome, aspirin, benefit, bleeding, cardiovascular disease (CVD), colorectal cancer (CRC), individualised choice, inflammation, personalised medicine, precision medicine, primary prevention, risk, secondary prevention, stroke, tertiary prevention |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10045216 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
